Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 22 May 2024 Status changed from active, no longer recruiting to completed.
- 23 Aug 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2025.
- 23 Aug 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2025.